药物治疗骨质疏松症的最新研究进展

来源 :中国中医骨伤科杂志 | 被引量 : 0次 | 上传用户:woheni123abc
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
骨质疏松症(Osteoporosis,OP)是以骨量减少,骨的微观结构退化为特征,使骨的脆性增加,以致发生骨折的一种全身性骨骼疾病。全世界约2亿多人患有骨质疏松,我国有超过8800万人,其中绝大多数为中、老年人,并且以绝经后的妇女占绝大多数,其发病率已跃居常见病、多发病的第七位。随着人口的老龄化,原发性骨质疏松症的发病率呈现明显的上升趋势,特别是由于骨质疏松而引起的骨折也越来越多,严重威胁着人类的生命和健康。 Osteoporosis (OP) is a systemic bone disease characterized by reduced bone mass and degenerated microstructure of the bone, which increases the fragility of the bone and causes fractures. About 200 million people in the world have osteoporosis. Over 88 million people in our country, the vast majority of whom are middle-aged and elderly, and the majority of women after menopause, the incidence rate has risen to common diseases, The seventh incidence of multiple. With the population aging, the incidence of primary osteoporosis shows a clear upward trend, especially due to osteoporosis caused by more and more fractures, a serious threat to human life and health.
其他文献